Table 1.

Other third-generation anti-CD19 CAR T-cell trials registered on ClinicalTrials.gov

Study ClinicalTrials.gov ID	B-cell malignancy subtypes	CAR generation	Study phase	Lymphodepletion	Study start date	Results published (yes/no)
NCT02963038	B-ALL+B-NHL	3G	I+II	Not specified	June 2016	No
NCT03068416	B-ALL+B-NHL	3G	II	Not specified	September 2017	No
NCT02132624 (see the Discussion section in paper)	B-NHL	3G	I	Flu 25 mg/m2×3 days, Cy 500 mg/m2×3 days	April 2014	Yes*
NCT03146533	B-NHL	3G	I+II	Flu 30 mg/m2×3 days Cy 800 mg/m2×3 days	April 2017	No
NCT01853631 (see the Discussion section in paper)	B-ALL+B-NHL	3G and 2G†	I	Flu 30 mg/m2×3 days, Cy 500 mg/m2×3 days	February 2014	Yes‡
NCT03676504	B-ALL+B-NHL	3G	I+II	Flu 30 mg/m2×3 days, Cy 500 mg/m2×3 days	September 2018	No
NCT02822326	B-ALL	3G	I	Flu 25 mg/m2×3 days Cy 300 mg/m2×3 days	January 2016	No

As at 16/09/2019.

*See Enblad et al. ²³

†Co-infused with CD28 containing second-generation CAR and CD28+41BB containing third-generation CAR.

‡See Ramos et al. ¹³

B-ALL, B-cell acute lymphoblastic leukaemia; B-NHL, B-cell non-Hodgkin's lymphoma; CAR, chimeric antigen receptor; Cy, cyclophosphamide; Flu, fludarabine.